Ted Buchan & Co Buys Shares of 1,330 Zoetis Inc. (NYSE:ZTS)

Ted Buchan & Co purchased a new position in shares of Zoetis Inc. (NYSE:ZTS) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 1,330 shares of the company’s stock, valued at approximately $231,000.

Several other large investors also recently made changes to their positions in the stock. Advisory Alpha LLC boosted its stake in shares of Zoetis by 23.6% during the 2nd quarter. Advisory Alpha LLC now owns 2,719 shares of the company’s stock worth $471,000 after acquiring an additional 520 shares in the last quarter. IMS Capital Management boosted its stake in shares of Zoetis by 11.3% during the 2nd quarter. IMS Capital Management now owns 2,958 shares of the company’s stock worth $543,000 after acquiring an additional 300 shares in the last quarter. Truist Financial Corp boosted its stake in shares of Zoetis by 1.5% during the 2nd quarter. Truist Financial Corp now owns 169,202 shares of the company’s stock worth $29,333,000 after acquiring an additional 2,557 shares in the last quarter. EP Wealth Advisors LLC boosted its stake in shares of Zoetis by 7.3% during the 2nd quarter. EP Wealth Advisors LLC now owns 230,512 shares of the company’s stock worth $39,961,000 after acquiring an additional 15,691 shares in the last quarter. Finally, Ecofi Investissements SA bought a new stake in shares of Zoetis during the 2nd quarter worth about $5,541,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.3 %

Zoetis stock opened at $195.38 on Tuesday. The business has a 50 day moving average price of $186.33 and a two-hundred day moving average price of $174.93. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. The stock has a market cap of $88.52 billion, a price-to-earnings ratio of 37.65, a price-to-earnings-growth ratio of 2.99 and a beta of 0.88. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. During the same period in the prior year, the firm posted $1.41 EPS. Zoetis’s quarterly revenue was up 8.3% compared to the same quarter last year. As a group, equities analysts forecast that Zoetis Inc. will post 5.84 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on ZTS shares. Piper Sandler increased their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. BTIG Research increased their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Stifel Nicolaus increased their target price on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $220.38.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.